Table 3.
Patients characteristics according to each risk factor with or without prior myocardial infarction (PMI)
| HTN | DL | DM | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PMI + | PMI- | P value | PMI+ | PMI- | P value | PMI+ | PMI- | P value | |
| n | 225 | 1039 | 245 | 973 | 144 | 533 | |||
| Age, y.o | 65.0 ± 10.5 | 65.7 ± 10.8 | 0.35 | 63.7 ± 10.5 | 64.6 ± 10.9 | 0.4 | 64.9 ± 10.1 | 66.8 ± 10.1 | <0.05 |
| Male, n | 201 (89.3%) | 774 (74.5%) | <0.001 | 217 (88.6%) | 731 (75.1%) | <0.0001 | 125 (86.8%) | 433 (80.9%) | 0.11 |
| BMI, kg/m2 | 24.8 ± 3.4 | 24.7 ± 3.6 | 0.58 | 24.9 ± 3.5 | 24.7 ± 3.5 | 0.45 | 24.4 ± 3.3 | 24.8 ± 3.8 | 0.25 |
| HTN, n | - | - | 188 (76.7%) | 730 (75.0%) | 0.62 | 110 (76.4%) | 417 (77.9%) | 0.74 | |
| DM, n | 188 (83.6%) | 730 (70.3%) | <0.001 | - | - | 118 (81.9%) | 410 (76.6%) | 0.21 | |
| DL, n | 110 (48.9%) | 417 (40.1%) | 0.02 | 118 (48.2%) | 410 (42.1%) | 0.1 | - | - | |
| Smoking, n | 106 (47.1%) | 448 (43.1%) | 0.3 | 117 (47.8%) | 454 (46.7%) | 0.77 | 72 (50.0%) | 268 (50.1%) | 0.98 |
| FH, n | 56 (24.9%) | 186 (17.9%) | 0.016 | 54 (22.0%) | 188 (19.3%) | 0.37 | 36 (25.0%) | 117 (21.9%) | 0.43 |
| eGFRa, ml/min/1.73 m2 | 66.5 ± 18.2 | 67.4 ± 17.6 | 0.49 | 66.9 ± 19.5 | 68.3 ± 17.1 | 0.32 | 69.5 ± 19.9 | 68.3 ± 18.6 | 0.54 |
| LDL, mg/dL | 101.4 ± 28.7 | 110.8 ± 29.7 | <0.0001 | 103.3 ± 30.2 | 114.0 ± 32.3 | <0.0001 | 103.3 ± 30.3 | 110.3 ± 29.4 | 0.02 |
| TGL, mg/dL | 151.7 ± 94.9 | 148.8 ± 89.6 | 0.69 | 154.6 ± 93.4 | 158.7 ± 103.4 | 0.61 | 155.3 ± 107.5 | 151.9 ± 89.2 | 0.72 |
| HbA1cb, % | 6.0 ± 1.1 | 5.9 ± 1.1 | 0.12 | 6.0 ± 1.3 | 5.9 ± 1.1 | 0.34 | 6.7 ± 1.4 | 6.7 ± 1.2 | 0.76 |
| UAc, mg/dL | 6.1 ± 1.3 | 5.9 ± 1.4 | 0.11 | 6.1 ± 1.3 | 5.8 ± 1.4 | 0.11 | 6.0 ± 1.5 | 5.8 ± 1.3 | 0.37 |
| BNPd, pg/mL | 78.9 ± 119.3 | 49.8 ± 69.1 | <0.01 | 83.9 ± 165.8 | 42.9 ± 54.2 | <0.001 | 75.0 ± 133.2 | 54.4 ± 65.7 | 0.16 |
| hs-CRP, mg/dL | 0.26 ± 0.64 | 0.23 ± 0.67 | 0.59 | 0.21 ± 0.54 | 0.25 ± 0.73 | 0.56 | 0.31 ± 0.73 | 0.30 ± 0.91 | 0.87 |
| Statin, n | 167 (74.2%) | 551 (53.0%) | <0.001 | 194 (79.2%) | 633 (65.1%) | <0.001 | 111 (77.1%) | 314 (58.7%) | <0.0001 |
| BB, n | 113 (50.2%) | 443 (42.6%) | 0.04 | 118 (48.2%) | 376 (38.7%) | <0.01 | 74 (51.4%) | 235 (43.9%) | 0.13 |
| ARBor ACEi, n | 158 (70.2%) | 628 (60.4%) | <0.01 | 157 (64.1%) | 479 (49.2%) | <0.0001 | 96 (66.7%) | 281 (52.5%) | <0.01 |
| EPA, μg/mL | 69.3 ± 36.5 | 75.1 ± 43.0 | 0.06 | 68.4 ± 36.2 | 76.4 ± 44.6 | <0.01 | 64.8 ± 33.1 | 75.5 ± 40.6 | <0.005 |
| DHA, μg/mL | 135.8 ± 47.8 | 145.8 ± 51.4 | <0.01 | 136.3 ± 49.8 | 149 ± 54.3 | <0.001 | 128.9 ± 41.1 | 143.1 ± 50.4 | <0.005 |
| AA, μg/mL | 153.4 ± 38.3 | 156.2 ± 40.8 | 0.35 | 157.4 ± 39.1 | 162.7 ± 43.0 | 0.08 | 154.4 ± 39.9 | 154.1 ± 41.3 | 0.75 |
| DHLA, μg/mL | 32.3 ± 11.9 | 33.5 ± 12.5 | 0.22 | 33.7 ± 11.9 | 34.9 ± 12.6 | 0.16 | 32.5 ± 11.6 | 33.5 ± 12.7 | 0.43 |
| EPA/AA | 0.47 ± 0.27 | 0.50 ± 0.30 | 0.19 | 0.46 ± 0.28 | 0.49 ± 0.29 | 0.21 | 0.45 ± 0.26 | 0.52 ± 0.29 | <0.01 |
| DHA/AA | 0.92 ± 0.35 | 0.97 ± 0.35 | 0.06 | 0.91 ± 0.36 | 0.95 ± 0.34 | 0.06 | 0.88 ± 0.32 | 0.97 ± 0.33 | <0.005 |
| EPA + DHA/AA + DHLA | 1.15 ± 0.03 | 1.22 ± 0.02 | 0.88 | 1.13 ± 0.49 | 1.19 ± 0.49 | 0.08 | 1.09 ± 0.44 | 1.22 ± 0.49 | <0.005 |
Continuous variables are presented as means ± standard deviations. Categorical variables are presented as percentages. Abbreviations are listed in the footnote to Table 1. anumbers of patients were 183 vs. 823, 201 vs. 736, and 119 vs. 416 (HTN with vs. without PMI, DL with vs. without PMI, and DM with vs. without PMI, respectively), bnumbers of patients were 181 vs. 809, 200 vs. 728, and 118 vs. 418 (same as above), cnumbers of patients were 91 vs. 450, 95 vs. 373, and 46 vs. 168 (same as above), dnumbers of patients were 87 vs. 412, 90 vs. 334, and 44 vs. 152 (same as above)